Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Asian Stocks Mixed Over Vaccines, U.S. Stimulus Measures Uncertainty

Published 04/12/2020, 01:38 pm
Updated 04/12/2020, 01:53 pm
© Reuters.
US500
-
AXJO
-
JP225
-
HK50
-
ALVG
-
PFE
-
KS11
-
SSEC
-
NABZY
-
202017
-
MRNA
-
BNTX
-

By Gina Lee       

Investing.com – Asia Pacific stocks were mixed on Friday morning, with investors continuing to take stock of global shares’ record rally in November and awaiting U.S. labor market data. News of potential supply-chain problems for a COVID-19 vaccine also capped gains. 

The data, including manufacturing payrolls  and non-farm payrolls, are due out later in the day. The data is expected to show modest gains in U.S. employment despite the country grappling with a second wave of COVID-19. 

Japan’s Nikkei 225 fell 0.43% by 10:31 PM ET (2:31 AM GMT)while South Korea’s KOSPI rose 1.64%.      

In Australia, the S&P/ASX 200 was up 0.32%. Australian retail sales grew 1.4% month-on-month in October, under the 1.6% growth in forecasts prepared by Investing.com but above the 1.1% contraction seen in September.  

Hong Kong’s Hang Seng Index edged up 0.11%.     

China’s Shanghai Composite fell 0.39and the Shenzhen Component was down 0.26%. 

Global shares remained just within reach of record highs over investor optimism that positive vaccine developments could sustain a global recovery in 2021. 

However, Pfizer Inc (NYSE:PFE) saw its shares decline as much as 3.1% during the previous session after a report claimed that it would ship only half of the expected doses of BNT162b2, its COVID-19 vaccine co-developed with BioNTech SE (NASDAQ:BNTX). Supply chain issues means that 50 million, not the originally anticipated 100 million, doses will be shipped.  

National Institute of Allergy and Infectious Diseases Anthony Fauci also slammed the U.K.’s Medicines and Healthcare products Regulatory Agency’s approval for BNT162b2, claiming that it was rushed. Fauci later apologized for his comments. 

Moderna Inc (NASDAQ:MRNA) also awaits U.S. and European approval for its candidate mRNA-1273, and released a study showing that its vaccine has the potential for durable immunity. 

Meanwhile, the number of global COVID-19 cases continues to rise. The number rose above 65 million as of Dec. 4, according to data from the Johns Hopkins University.  In the U.S., California warned that it will lock down its economy if its critical-care capacity reaches its limit. President-elect Joe Biden also said he would ask all Americans to wear a mask to prevent the spread of COVID-19 for the first 100 days of his administration. 

"The U.S. fiscal situation is pretty fluid, but it's more encouraging than in the beginning of the week … but there's too much uncertainty to do anything with a great degree of confidence." National Australia Bank (OTC:NABZY) head of FX strategy Ray Attrill told Reuters. 

The uncertainty extends to the latest U.S. stimulus packages, with a Dec. 11 deadline to avert a government shutdown looming. However, proposed $908 billion bipartisan package was slowly gaining traction in Congress on Thursday.  

However, some investors remained optimistic. 

“If we do see earnings growth start to pick up, perhaps 25% to 30% on the S&P 500 next year, and if we see rates remain low and stimulus in place, that remains a good backdrop for risk assets,” Allianz (DE:ALVG) Global Investors investment strategist Mona Mahajan told Bloomberg. 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.